Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Randomized, Double-blind, Parallel-controlled Versus Placebo in a Polyvalent Sublingual Bacterial Vaccine to 3 Months and 6 Months in Women With RUTI for the Immunomodulatory Efficacy Evaluation, Safety and Clinical Impact

Next Previous
Search
Trial Profile

Prospective Randomized, Double-blind, Parallel-controlled Versus Placebo in a Polyvalent Sublingual Bacterial Vaccine to 3 Months and 6 Months in Women With RUTI for the Immunomodulatory Efficacy Evaluation, Safety and Clinical Impact

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enterococcus-faecalis-FK23/escherichia-coli-vaccine/klebsiella-vaccine/proteus-vulgaris-inactivated-vaccine (Primary)
  • Indications Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Inmunotek

    • Most Recent Events

    • 16 May 2022 Results presented at the 117th Annual Meeting of the American Urological Association
    • 17 Oct 2021 Results presented at the 51st Annual Meeting of the International Continence Society
    • 13 Sep 2021 Results from NCT02543827 and other studies assessing benefits of MV140 vaccine as a safe and effective strategy to reduce the incidence and/or prevent rUTI , presented at the 116th Annual Meeting of the American Urological Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top